ong-term efficacy and safety of the GLP-1 receptor agonist liraglutide in Japanese patients with type 2 diabetes mellitus.
Not Applicable
- Conditions
- Type 2 Diabetes mellitus
- Registration Number
- JPRN-UMIN000037603
- Lead Sponsor
- akakinen clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Not provided
Exclusion Criteria
Participation in the study is judged by the investigator or sub-investigator as inappropriate for any other reason
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change in the eGFR slope and urine albumin creatinine ratio
- Secondary Outcome Measures
Name Time Method Metabolic marker; HbA1c and body weight Hemodynamic marker; systolic and diastolic blood pressure, and heart rate Liver enzyme marker; AST, ALT and gamma-GTP Liver fibrosis marker; Fib-4 index Arteriosclerosis marker; IMT and PWV Safety marker; incidence rate of Hypoglycemia